Eurofins Clinical Enterprise, LLC and SeqMatic first providers to join program, expanding access to Parse’s growing single cell portfolio

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of its Certified Service Provider (CSP) Program. For researchers who are seeking paths to outsource their single cell projects, Parse’s CSP Program provides options to partner with trusted service providers capable of running smaller pilot projects up to performing routine high throughput projects.

Fremont, California-based SeqMatic and Framingham, Massachusetts-based Eurofins Clinical Enterprise, LLC are the first CSPs to partner with Parse to offer its expanding portfolio of single cell products, including its Evercode™ Whole Transcriptome, Evercode™ TCR, CRISPR Detect, Gene Capture, and its recently released Evercode™ BCR, which captures full length BCR sequences and gene expression together at unprecedented scale.

“The advances we’re seeing as a result of single cell sequencing continue to transform scientific research,” noted Parse co-founder and CEO Alex Rosenberg. “The CSP Program is an important step in broadening access to scalable single cell sequencing, and we’re proud to have SeqMatic and Eurofins Clinical Enterprise join us as our first partners in this initiative.”

Comprehensive CSPs providing a full range of high quality end-to-end multi omics workflow solutions including DNA and RNA sequencing, SeqMatic and Eurofins Clinical Enterprise can manage samples from any US or international location, including multi-site collaborations and unique requirements. Their professional service provides assurance of expert handling, tracking and coordination of samples.

“SeqMatic is dedicated to providing the highest level of service and cutting edge technologies to our more than 700 customers in the US and around the world,” said SeqMatic CEO Len Goren. “We are excited to make Parse’s industry-leading single cell sequencing kits available to all of them.”

Partner companies like SeqMatic and Eurofins Clinical Enterprise that offer Parse’s kits as a service must meet Parse’s stringent criteria and provide the highest quality results to their clients. For more information about Parse’s CSP program, visit https://www.parsebiosciences.com/service-providers/. To learn more about SeqMatic’s Parse offerings, visit https://www.seqmatic.com/services/parse-biosciences-single-cell-rna-sequencing-service/, and to learn more about Eurofins Clinical Enterprise’s Parse offerings, visit https://clinicalenterprise.com/.

About Parse Biosciences

Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach is enabling groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.

Founded based on a transformative technology invented at the University of Washington, Parse has raised over $100 million and is used in nearly 2,000 labs across the world. Its growing portfolio of products includes Evercode Whole Transcriptome, Evercode TCR, Evercode BCR, CRISPR Detect, Gene Capture, and a software tool for data analysis.

Headquartered in Seattle, Washington’s vibrant South Lake Union district, Parse Biosciences recently opened a 34,000 square foot headquarters and state-of-the-art laboratory.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240711445815/en/